drugs like lupron give a testosterone surge which is the opposite effect that you want to give a person with prostate cancer
the problem was that in rare occasions (a couple of people in the trials got a life threatening infection. I don't know what kind of infection though.
The company doesn't know what caused the infection so there was no way to figure out who shouldn't get the drug. The risk benefit was then a rare chance to die versus avoiding the testosterone surge.
Market Data 
Markets 
AI
